Share Price and Basic Stock Data
Last Updated: December 30, 2025, 2:39 am
| PEG Ratio | 19.71 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
FDC Ltd operates in the pharmaceuticals sector, with a current market capitalization of ₹6,630 Cr and a stock price of ₹407. The company reported a steady increase in sales, which rose from ₹1,525 Cr in March 2022 to ₹1,784 Cr in March 2023, and is projected to reach ₹2,108 Cr by March 2025. Quarterly sales showed fluctuations, peaking at ₹638 Cr in June 2024. The company’s operational efficiency is indicated by its operating profit margin (OPM), which stood at 22% in the latest quarter. Such trends suggest that FDC is effectively navigating market dynamics, evidenced by a trailing twelve months (TTM) revenue of ₹2,077 Cr. Overall, the revenue trajectory illustrates a robust growth pattern, aligning with the increasing demand within the pharmaceutical industry in India.
Profitability and Efficiency Metrics
FDC Ltd’s profitability metrics reflect a mixed performance. The net profit of ₹225 Cr demonstrates resilience, with a net profit margin of 12.65% as of March 2025. The OPM has shown variability, with a high of 23% in June 2023 and a low of 10% in December 2024. Additionally, the company’s return on equity (ROE) stood at 11.8%, while return on capital employed (ROCE) was recorded at 15.9%. These figures are relatively competitive within the pharmaceutical sector, where ROE typically ranges from 12% to 18%. The interest coverage ratio (ICR) is impressive at 92.13x, indicating strong earnings relative to interest obligations, which positions FDC favorably against industry peers. However, the cash conversion cycle (CCC) of 103 days suggests potential inefficiencies in managing working capital.
Balance Sheet Strength and Financial Ratios
The balance sheet of FDC Ltd exhibits a solid foundation, with total reserves amounting to ₹2,415 Cr against borrowings of just ₹21 Cr. This low level of debt enhances financial stability, reflected in the company’s high current ratio of 3.01x and quick ratio of 1.97x, which are well above typical sector thresholds. The price-to-book value (P/BV) ratio stood at 2.81x, indicating that the market values the company’s equity higher than its book value, a positive signal for investors. However, the company’s asset turnover ratio of 0.81 suggests that FDC may not be using its assets as efficiently as possible to generate revenue. Overall, the balance sheet metrics support a strong liquidity position, but operational efficiency could be further optimized to improve asset utilization.
Shareholding Pattern and Investor Confidence
FDC Ltd’s shareholding structure reveals a significant promoter ownership of 69.66%, indicating strong control and confidence from the management. Foreign institutional investors (FIIs) hold 2.43%, while domestic institutional investors (DIIs) account for 6.81%, reflecting moderate institutional interest. The public shareholding stands at 21.10%, with a total of 54,157 shareholders as of the latest reports. This distribution suggests a stable base of retail and institutional investors, although the relatively low FII participation may limit broader investor confidence. Over recent quarters, the number of shareholders has gradually declined, from 59,871 in December 2022 to 54,157 in September 2025, which could signal a need for improved investor engagement strategies to attract new investors.
Outlook, Risks, and Final Insight
Looking ahead, FDC Ltd is well-positioned for growth given its strong revenue trends and financial health. However, risks remain, particularly in operational efficiency and market competition. The volatility in the OPM and fluctuations in quarterly sales could hinder profitability if not addressed. Additionally, the increasing pressure from generic drug manufacturers and regulatory changes in the pharmaceutical sector pose challenges. To capitalize on its strengths, FDC should focus on enhancing its asset turnover and reducing the cash conversion cycle. If operational efficiencies improve, the company could further bolster its profitability and investor confidence. Conversely, failure to adapt to market dynamics may impact its growth trajectory. Overall, FDC Ltd’s strong fundamentals provide a promising outlook, contingent on its ability to navigate industry challenges effectively.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 122 Cr. | 97.0 | 231/84.3 | 27.0 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.54 Cr. | 1.85 | 4.29/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,881 Cr. | 448 | 479/192 | 101 | 24.3 | 0.15 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 32.9 Cr. | 44.3 | 88.6/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 50.8 Cr. | 34.7 | 35.0/17.0 | 121 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,055.07 Cr | 1,146.57 | 52.84 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 495 | 445 | 409 | 435 | 536 | 486 | 458 | 462 | 638 | 514 | 464 | 492 | 648 |
| Expenses | 417 | 378 | 360 | 386 | 414 | 410 | 374 | 406 | 492 | 444 | 417 | 438 | 508 |
| Operating Profit | 78 | 67 | 49 | 49 | 122 | 76 | 84 | 56 | 147 | 70 | 47 | 54 | 140 |
| OPM % | 16% | 15% | 12% | 11% | 23% | 16% | 18% | 12% | 23% | 14% | 10% | 11% | 22% |
| Other Income | 19 | 13 | 18 | 7 | 29 | 27 | 25 | 20 | 28 | 35 | 19 | 16 | 36 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 9 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 11 | 14 | 13 | 16 | 15 |
| Profit before tax | 87 | 69 | 57 | 45 | 141 | 93 | 98 | 65 | 163 | 90 | 51 | 53 | 160 |
| Tax % | 19% | 25% | 28% | 32% | 22% | 25% | 19% | 29% | 27% | 20% | 28% | 27% | 24% |
| Net Profit | 71 | 52 | 41 | 31 | 110 | 70 | 79 | 46 | 119 | 72 | 37 | 39 | 121 |
| EPS in Rs | 4.26 | 3.12 | 2.46 | 1.85 | 6.62 | 4.29 | 4.87 | 2.84 | 7.31 | 4.42 | 2.28 | 2.38 | 7.45 |
Last Updated: August 20, 2025, 11:00 am
Below is a detailed analysis of the quarterly data for FDC Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 648.00 Cr.. The value appears strong and on an upward trend. It has increased from 492.00 Cr. (Mar 2025) to 648.00 Cr., marking an increase of 156.00 Cr..
- For Expenses, as of Jun 2025, the value is 508.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 438.00 Cr. (Mar 2025) to 508.00 Cr., marking an increase of 70.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 140.00 Cr.. The value appears strong and on an upward trend. It has increased from 54.00 Cr. (Mar 2025) to 140.00 Cr., marking an increase of 86.00 Cr..
- For OPM %, as of Jun 2025, the value is 22.00%. The value appears strong and on an upward trend. It has increased from 11.00% (Mar 2025) to 22.00%, marking an increase of 11.00%.
- For Other Income, as of Jun 2025, the value is 36.00 Cr.. The value appears strong and on an upward trend. It has increased from 16.00 Cr. (Mar 2025) to 36.00 Cr., marking an increase of 20.00 Cr..
- For Interest, as of Jun 2025, the value is 1.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 1.00 Cr..
- For Depreciation, as of Jun 2025, the value is 15.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 16.00 Cr. (Mar 2025) to 15.00 Cr., marking a decrease of 1.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 160.00 Cr.. The value appears strong and on an upward trend. It has increased from 53.00 Cr. (Mar 2025) to 160.00 Cr., marking an increase of 107.00 Cr..
- For Tax %, as of Jun 2025, the value is 24.00%. The value appears to be improving (decreasing) as expected. It has decreased from 27.00% (Mar 2025) to 24.00%, marking a decrease of 3.00%.
- For Net Profit, as of Jun 2025, the value is 121.00 Cr.. The value appears strong and on an upward trend. It has increased from 39.00 Cr. (Mar 2025) to 121.00 Cr., marking an increase of 82.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 7.45. The value appears strong and on an upward trend. It has increased from 2.38 (Mar 2025) to 7.45, marking an increase of 5.07.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:23 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 845 | 888 | 994 | 1,013 | 1,074 | 1,089 | 1,341 | 1,331 | 1,525 | 1,784 | 1,943 | 2,108 | 2,077 |
| Expenses | 638 | 690 | 765 | 769 | 841 | 860 | 1,038 | 997 | 1,271 | 1,533 | 1,604 | 1,783 | 1,803 |
| Operating Profit | 207 | 199 | 229 | 243 | 233 | 229 | 304 | 334 | 254 | 251 | 339 | 325 | 275 |
| OPM % | 24% | 22% | 23% | 24% | 22% | 21% | 23% | 25% | 17% | 14% | 17% | 15% | 13% |
| Other Income | 39 | 46 | 39 | 44 | 45 | 42 | 57 | 95 | 76 | 50 | 102 | 91 | 91 |
| Interest | 3 | 2 | 1 | 1 | 1 | 1 | 3 | 3 | 3 | 4 | 4 | 5 | 4 |
| Depreciation | 25 | 39 | 34 | 35 | 35 | 33 | 37 | 38 | 37 | 39 | 40 | 54 | 59 |
| Profit before tax | 218 | 204 | 232 | 252 | 241 | 237 | 320 | 388 | 289 | 258 | 396 | 357 | 302 |
| Tax % | 38% | 27% | 27% | 25% | 28% | 28% | 25% | 22% | 25% | 25% | 23% | 25% | |
| Net Profit | 135 | 148 | 169 | 189 | 174 | 170 | 240 | 301 | 216 | 194 | 305 | 267 | 225 |
| EPS in Rs | 7.61 | 8.33 | 9.48 | 10.60 | 9.95 | 9.74 | 14.03 | 17.85 | 12.82 | 11.70 | 18.75 | 16.39 | 13.85 |
| Dividend Payout % | 30% | 27% | 24% | 21% | 0% | 0% | 6% | 0% | 0% | 0% | 0% | 31% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 9.63% | 14.19% | 11.83% | -7.94% | -2.30% | 41.18% | 25.42% | -28.24% | -10.19% | 57.22% | -12.46% |
| Change in YoY Net Profit Growth (%) | 0.00% | 4.56% | -2.35% | -19.77% | 5.64% | 43.48% | -15.76% | -53.66% | 18.05% | 67.40% | -69.68% |
FDC Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 9% |
| 5 Years: | 9% |
| 3 Years: | 11% |
| TTM: | 4% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 2% |
| 3 Years: | 7% |
| TTM: | -14% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 9% |
| 5 Years: | 8% |
| 3 Years: | 18% |
| 1 Year: | -18% |
| Return on Equity | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | 13% |
| 3 Years: | 12% |
| Last Year: | 12% |
Last Updated: September 5, 2025, 3:55 am
Balance Sheet
Last Updated: December 10, 2025, 2:39 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 18 | 18 | 18 | 18 | 18 | 18 | 17 | 17 | 17 | 17 | 16 | 16 | 16 |
| Reserves | 827 | 919 | 1,065 | 1,252 | 1,259 | 1,428 | 1,530 | 1,717 | 1,940 | 1,965 | 2,081 | 2,265 | 2,415 |
| Borrowings | 3 | 2 | 1 | 1 | 1 | 1 | 15 | 15 | 32 | 28 | 21 | 21 | 21 |
| Other Liabilities | 211 | 210 | 182 | 197 | 228 | 194 | 250 | 207 | 281 | 333 | 350 | 412 | 433 |
| Total Liabilities | 1,059 | 1,148 | 1,266 | 1,468 | 1,505 | 1,640 | 1,813 | 1,956 | 2,270 | 2,343 | 2,468 | 2,714 | 2,886 |
| Fixed Assets | 284 | 393 | 675 | 678 | 674 | 682 | 674 | 689 | 705 | 699 | 680 | 852 | 842 |
| CWIP | 18 | 29 | 20 | 6 | 13 | 12 | 24 | 19 | 105 | 198 | 261 | 137 | 163 |
| Investments | 417 | 489 | 325 | 491 | 471 | 585 | 665 | 790 | 886 | 806 | 843 | 1,028 | 1,007 |
| Other Assets | 340 | 237 | 246 | 293 | 348 | 360 | 451 | 458 | 575 | 640 | 684 | 698 | 874 |
| Total Assets | 1,059 | 1,148 | 1,266 | 1,468 | 1,505 | 1,640 | 1,813 | 1,956 | 2,270 | 2,343 | 2,468 | 2,714 | 2,886 |
Below is a detailed analysis of the balance sheet data for FDC Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 16.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 16.00 Cr..
- For Reserves, as of Sep 2025, the value is 2,415.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,265.00 Cr. (Mar 2025) to 2,415.00 Cr., marking an increase of 150.00 Cr..
- For Borrowings, as of Sep 2025, the value is 21.00 Cr.. The value remains steady. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. There is no change compared to the previous period (Mar 2025) which recorded 21.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 433.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 412.00 Cr. (Mar 2025) to 433.00 Cr., marking an increase of 21.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 2,886.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2,714.00 Cr. (Mar 2025) to 2,886.00 Cr., marking an increase of 172.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 842.00 Cr.. The value appears to be declining and may need further review. It has decreased from 852.00 Cr. (Mar 2025) to 842.00 Cr., marking a decrease of 10.00 Cr..
- For CWIP, as of Sep 2025, the value is 163.00 Cr.. The value appears strong and on an upward trend. It has increased from 137.00 Cr. (Mar 2025) to 163.00 Cr., marking an increase of 26.00 Cr..
- For Investments, as of Sep 2025, the value is 1,007.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,028.00 Cr. (Mar 2025) to 1,007.00 Cr., marking a decrease of 21.00 Cr..
- For Other Assets, as of Sep 2025, the value is 874.00 Cr.. The value appears strong and on an upward trend. It has increased from 698.00 Cr. (Mar 2025) to 874.00 Cr., marking an increase of 176.00 Cr..
- For Total Assets, as of Sep 2025, the value is 2,886.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,714.00 Cr. (Mar 2025) to 2,886.00 Cr., marking an increase of 172.00 Cr..
Notably, the Reserves (2,415.00 Cr.) exceed the Borrowings (21.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 204.00 | 197.00 | 228.00 | 242.00 | 232.00 | 228.00 | 289.00 | 319.00 | 222.00 | 223.00 | 318.00 | 304.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 26 | 25 | 23 | 27 | 28 | 29 | 34 | 30 | 20 | 25 | 22 | 19 |
| Inventory Days | 116 | 132 | 134 | 148 | 166 | 184 | 180 | 189 | 210 | 183 | 216 | 186 |
| Days Payable | 90 | 94 | 84 | 81 | 101 | 82 | 101 | 68 | 94 | 99 | 103 | 102 |
| Cash Conversion Cycle | 51 | 64 | 72 | 94 | 93 | 131 | 113 | 152 | 135 | 109 | 135 | 103 |
| Working Capital Days | 1 | 11 | 21 | 23 | 29 | 45 | 40 | 48 | 45 | 48 | 53 | 33 |
| ROCE % | 25% | 21% | 22% | 21% | 19% | 17% | 21% | 22% | 15% | 13% | 18% | 16% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Nippon India Small Cap Fund | 4,275,331 | 0.26 | 177.17 | 4,257,262 | 2025-12-08 07:42:13 | 0.42% |
| ICICI Prudential Smallcap Fund | 1,930,587 | 0.95 | 80 | 1,926,874 | 2025-12-14 01:15:32 | 0.19% |
| ICICI Prudential Pharma Healthcare & Diagnostics (P.H.D) Fund | 1,197,689 | 0.77 | 49.63 | N/A | N/A | N/A |
| Tata India Pharma & HealthCare Fund | 927,104 | 2.87 | 38.42 | 841,720 | 2025-12-15 04:05:07 | 10.14% |
| ICICI Prudential ESG Exclusionary Strategy Fund | 659,323 | 1.81 | 27.32 | 559,323 | 2025-12-14 01:15:33 | 17.88% |
| ICICI Prudential MNC Fund | 486,581 | 1.15 | 20.16 | N/A | N/A | N/A |
| Bandhan Small Cap Fund | 446,288 | 0.1 | 18.49 | N/A | N/A | N/A |
| ICICI Prudential Bharat Consumption Fund | 214,632 | 0.27 | 8.89 | N/A | N/A | N/A |
| ITI Pharma and Healthcare Fund | 76,179 | 1.37 | 3.16 | 70,933 | 2025-12-15 04:31:04 | 7.4% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Basic EPS (Rs.) | 16.39 | 18.58 | 11.66 | 12.81 | 17.72 |
| Diluted EPS (Rs.) | 16.39 | 18.58 | 11.66 | 12.81 | 17.72 |
| Cash EPS (Rs.) | 19.69 | 21.19 | 14.03 | 15.01 | 20.08 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 140.11 | 128.81 | 119.43 | 115.89 | 102.72 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 140.11 | 128.81 | 119.43 | 115.89 | 102.72 |
| Revenue From Operations / Share (Rs.) | 129.48 | 119.34 | 107.51 | 90.51 | 78.98 |
| PBDIT / Share (Rs.) | 25.52 | 27.04 | 18.13 | 19.54 | 25.54 |
| PBIT / Share (Rs.) | 22.22 | 24.58 | 15.79 | 17.33 | 23.30 |
| PBT / Share (Rs.) | 21.94 | 24.34 | 15.54 | 17.14 | 22.97 |
| Net Profit / Share (Rs.) | 16.39 | 18.74 | 11.68 | 12.81 | 17.84 |
| NP After MI And SOA / Share (Rs.) | 16.39 | 18.75 | 11.70 | 12.82 | 17.85 |
| PBDIT Margin (%) | 19.70 | 22.65 | 16.86 | 21.58 | 32.33 |
| PBIT Margin (%) | 17.15 | 20.60 | 14.68 | 19.14 | 29.49 |
| PBT Margin (%) | 16.94 | 20.39 | 14.45 | 18.94 | 29.08 |
| Net Profit Margin (%) | 12.65 | 15.70 | 10.86 | 14.14 | 22.59 |
| NP After MI And SOA Margin (%) | 12.65 | 15.70 | 10.87 | 14.16 | 22.60 |
| Return on Networth / Equity (%) | 11.69 | 14.55 | 9.78 | 11.05 | 17.37 |
| Return on Capital Employeed (%) | 15.37 | 18.55 | 12.89 | 14.63 | 22.44 |
| Return On Assets (%) | 9.83 | 12.36 | 8.28 | 9.53 | 15.40 |
| Asset Turnover Ratio (%) | 0.81 | 0.80 | 0.77 | 0.72 | 0.70 |
| Current Ratio (X) | 3.01 | 3.43 | 3.30 | 3.67 | 4.58 |
| Quick Ratio (X) | 1.97 | 2.18 | 2.24 | 2.56 | 3.52 |
| Inventory Turnover Ratio (X) | 5.52 | 1.63 | 1.85 | 1.75 | 1.64 |
| Dividend Payout Ratio (NP) (%) | 30.51 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 25.39 | 0.00 | 0.00 | 0.00 | 0.00 |
| Earning Retention Ratio (%) | 69.49 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Earning Retention Ratio (%) | 74.61 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio (X) | 92.13 | 109.11 | 73.60 | 106.74 | 125.53 |
| Interest Coverage Ratio (Post Tax) (X) | 60.16 | 76.62 | 48.42 | 70.97 | 89.32 |
| Enterprise Value (Cr.) | 6366.94 | 6886.08 | 4231.47 | 4298.40 | 4791.75 |
| EV / Net Operating Revenue (X) | 3.02 | 3.54 | 2.37 | 2.81 | 3.59 |
| EV / EBITDA (X) | 15.32 | 15.64 | 14.07 | 13.03 | 11.12 |
| MarketCap / Net Operating Revenue (X) | 3.05 | 3.56 | 2.39 | 2.84 | 3.62 |
| Retention Ratios (%) | 69.48 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price / BV (X) | 2.81 | 3.30 | 2.15 | 2.22 | 2.78 |
| Price / Net Operating Revenue (X) | 3.05 | 3.56 | 2.39 | 2.84 | 3.62 |
| EarningsYield | 0.04 | 0.04 | 0.04 | 0.04 | 0.06 |
After reviewing the key financial ratios for FDC Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 16.39. This value is within the healthy range. It has decreased from 18.58 (Mar 24) to 16.39, marking a decrease of 2.19.
- For Diluted EPS (Rs.), as of Mar 25, the value is 16.39. This value is within the healthy range. It has decreased from 18.58 (Mar 24) to 16.39, marking a decrease of 2.19.
- For Cash EPS (Rs.), as of Mar 25, the value is 19.69. This value is within the healthy range. It has decreased from 21.19 (Mar 24) to 19.69, marking a decrease of 1.50.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 140.11. It has increased from 128.81 (Mar 24) to 140.11, marking an increase of 11.30.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 140.11. It has increased from 128.81 (Mar 24) to 140.11, marking an increase of 11.30.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 129.48. It has increased from 119.34 (Mar 24) to 129.48, marking an increase of 10.14.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 25.52. This value is within the healthy range. It has decreased from 27.04 (Mar 24) to 25.52, marking a decrease of 1.52.
- For PBIT / Share (Rs.), as of Mar 25, the value is 22.22. This value is within the healthy range. It has decreased from 24.58 (Mar 24) to 22.22, marking a decrease of 2.36.
- For PBT / Share (Rs.), as of Mar 25, the value is 21.94. This value is within the healthy range. It has decreased from 24.34 (Mar 24) to 21.94, marking a decrease of 2.40.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 16.39. This value is within the healthy range. It has decreased from 18.74 (Mar 24) to 16.39, marking a decrease of 2.35.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 16.39. This value is within the healthy range. It has decreased from 18.75 (Mar 24) to 16.39, marking a decrease of 2.36.
- For PBDIT Margin (%), as of Mar 25, the value is 19.70. This value is within the healthy range. It has decreased from 22.65 (Mar 24) to 19.70, marking a decrease of 2.95.
- For PBIT Margin (%), as of Mar 25, the value is 17.15. This value is within the healthy range. It has decreased from 20.60 (Mar 24) to 17.15, marking a decrease of 3.45.
- For PBT Margin (%), as of Mar 25, the value is 16.94. This value is within the healthy range. It has decreased from 20.39 (Mar 24) to 16.94, marking a decrease of 3.45.
- For Net Profit Margin (%), as of Mar 25, the value is 12.65. This value exceeds the healthy maximum of 10. It has decreased from 15.70 (Mar 24) to 12.65, marking a decrease of 3.05.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 12.65. This value is within the healthy range. It has decreased from 15.70 (Mar 24) to 12.65, marking a decrease of 3.05.
- For Return on Networth / Equity (%), as of Mar 25, the value is 11.69. This value is below the healthy minimum of 15. It has decreased from 14.55 (Mar 24) to 11.69, marking a decrease of 2.86.
- For Return on Capital Employeed (%), as of Mar 25, the value is 15.37. This value is within the healthy range. It has decreased from 18.55 (Mar 24) to 15.37, marking a decrease of 3.18.
- For Return On Assets (%), as of Mar 25, the value is 9.83. This value is within the healthy range. It has decreased from 12.36 (Mar 24) to 9.83, marking a decrease of 2.53.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.81. It has increased from 0.80 (Mar 24) to 0.81, marking an increase of 0.01.
- For Current Ratio (X), as of Mar 25, the value is 3.01. This value exceeds the healthy maximum of 3. It has decreased from 3.43 (Mar 24) to 3.01, marking a decrease of 0.42.
- For Quick Ratio (X), as of Mar 25, the value is 1.97. This value is within the healthy range. It has decreased from 2.18 (Mar 24) to 1.97, marking a decrease of 0.21.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 5.52. This value is within the healthy range. It has increased from 1.63 (Mar 24) to 5.52, marking an increase of 3.89.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 30.51. This value is within the healthy range. It has increased from 0.00 (Mar 24) to 30.51, marking an increase of 30.51.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 25.39. This value is within the healthy range. It has increased from 0.00 (Mar 24) to 25.39, marking an increase of 25.39.
- For Earning Retention Ratio (%), as of Mar 25, the value is 69.49. This value is within the healthy range. It has increased from 0.00 (Mar 24) to 69.49, marking an increase of 69.49.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 74.61. This value exceeds the healthy maximum of 70. It has increased from 0.00 (Mar 24) to 74.61, marking an increase of 74.61.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 92.13. This value is within the healthy range. It has decreased from 109.11 (Mar 24) to 92.13, marking a decrease of 16.98.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 60.16. This value is within the healthy range. It has decreased from 76.62 (Mar 24) to 60.16, marking a decrease of 16.46.
- For Enterprise Value (Cr.), as of Mar 25, the value is 6,366.94. It has decreased from 6,886.08 (Mar 24) to 6,366.94, marking a decrease of 519.14.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 3.02. This value exceeds the healthy maximum of 3. It has decreased from 3.54 (Mar 24) to 3.02, marking a decrease of 0.52.
- For EV / EBITDA (X), as of Mar 25, the value is 15.32. This value exceeds the healthy maximum of 15. It has decreased from 15.64 (Mar 24) to 15.32, marking a decrease of 0.32.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 3.05. This value exceeds the healthy maximum of 3. It has decreased from 3.56 (Mar 24) to 3.05, marking a decrease of 0.51.
- For Retention Ratios (%), as of Mar 25, the value is 69.48. This value is within the healthy range. It has increased from 0.00 (Mar 24) to 69.48, marking an increase of 69.48.
- For Price / BV (X), as of Mar 25, the value is 2.81. This value is within the healthy range. It has decreased from 3.30 (Mar 24) to 2.81, marking a decrease of 0.49.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 3.05. This value exceeds the healthy maximum of 3. It has decreased from 3.56 (Mar 24) to 3.05, marking a decrease of 0.51.
- For EarningsYield, as of Mar 25, the value is 0.04. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.04.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in FDC Ltd:
- Net Profit Margin: 12.65%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 15.37% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 11.69% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 60.16
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.97
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 30.7 (Industry average Stock P/E: 52.84)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 12.65%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | B-8, MIDC Industrial Estate, Aurangabad District Maharashtra 431136 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| CA. Uday Kumar Gurkar | Chairman & Ind.Director |
| Mr. Mohan A Chandavarkar | Managing Director |
| Mr. Nandan M Chandavarkar | Joint Managing Director |
| Mr. Ameya A Chandavarkar | Executive Director & CEO |
| Mr. Ashok A Chandavarkar | Executive Director |
| Ms. Nomita R Chandavarkar | Non Exe.Non Ind.Director |
| Dr. Mahesh Bijlani | Independent Director |
| Mr. Vijay Maniar | Independent Director |
| Mr. Vijay Nautamlal Bhatt | Independent Director |
| Dr. Charuta Nityanath Mandke | Independent Director |
FAQ
What is the intrinsic value of FDC Ltd?
FDC Ltd's intrinsic value (as of 30 December 2025) is 436.91 which is 2.80% higher the current market price of 425.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 6,922 Cr. market cap, FY2025-2026 high/low of 528/359, reserves of ₹2,415 Cr, and liabilities of 2,886 Cr.
What is the Market Cap of FDC Ltd?
The Market Cap of FDC Ltd is 6,922 Cr..
What is the current Stock Price of FDC Ltd as on 30 December 2025?
The current stock price of FDC Ltd as on 30 December 2025 is 425.
What is the High / Low of FDC Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of FDC Ltd stocks is 528/359.
What is the Stock P/E of FDC Ltd?
The Stock P/E of FDC Ltd is 30.7.
What is the Book Value of FDC Ltd?
The Book Value of FDC Ltd is 149.
What is the Dividend Yield of FDC Ltd?
The Dividend Yield of FDC Ltd is 1.18 %.
What is the ROCE of FDC Ltd?
The ROCE of FDC Ltd is 15.9 %.
What is the ROE of FDC Ltd?
The ROE of FDC Ltd is 11.8 %.
What is the Face Value of FDC Ltd?
The Face Value of FDC Ltd is 1.00.